In the latest issue of Med-Tech Innovation, Shada Azodi, Research Director at Bold Insight, explores the intersection of FemTech, user experience (UX) research, and digital inclusion. The article, Unveiling the lessons of the FemTech revolution, emphasises the transformative power of inclusive design and user-centric approaches in this growing industry.
“FemTech brings invaluable lessons to the healthcare industry,” said Azodi. “From empowering women’s health to driving innovation, this revolution is reshaping the future of healthcare.”
A digitally-inclusive future includes integrating FemTech research into the design and development of digital products and services. The lessons from the FemTech revolution are a reminder of the transformative impact that inclusive design can have, shaping a more equitable digital landscape for all.
Azodi recently launched a London FemTech UX group and co-presented a webinar with Martin Porcheron, Senior Researcher at Bold Insight, on How to deliver a better FemTech experience: UX considerations, sharing their experiences and insights acquired from working with FemTech companies.
Read the full article by visiting the Med-Tech Innovation website.
About Med-Tech Innovation
Med-Tech Innovation is a leading multi-platform communication brand for the UK and Ireland’s medical design and manufacturing industry. Working across digital and print media platforms, Med-Tech Innovation delivers messages direct to a unique medical and healthcare audience looking to source solutions to their latest challenges.
About Bold Insight
Bold Insight is a user experience and human factors research agency based in London and Chicago. Our work spans the product development life cycle – from early product design to global human factors validation – all to ensure the user experience is useful, usable, and satisfying. We work with digital, next-generation technology including medical devices, mobile apps, in-car systems, home appliances and more, delivering research-based insights to empower confidence in design.
0 Comments